Porphyrin analogues as novel antagonists of fibroblast growth factor and vascular endothelial growth factor receptor binding that inhibit endothelial cell proliferation, tumor progression, and metastasis

Cancer Research

Volumn 60, Issue 11, 2000, Pages 2973-2980

  Aviezer, David ^a,c   Cotton, Sara ^a   David, Magda ^a   Segev, Amit ^a   Khaselev, Nona ^b   Galili, Nitsa ^b   Gross, Zeev ^b   Yayon, Avner ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c ProChon Biotech Ltd   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; PORPHYRIN DERIVATIVE; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; CANCER INHIBITION; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; ENDOTHELIUM CELL; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING;

ANIMALS; AORTA; CARCINOMA, LEWIS LUNG; CELL DIVISION; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; FIBROBLAST GROWTH FACTOR 2; HUMANS; LUNG NEOPLASMS; MALE; MICE; NEOPLASMS, EXPERIMENTAL; PHENOTYPE; PORPHYRINS; PROTEIN BINDING; RATS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; TIME FACTORS;

EID: 0034214085     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Klagsbrun, M. The fibroblast growth factor family: structural and biological properties. Progress Growth Factor Res., 1: 207-235, 1989.
2. Folkman, J., and Klagsburn, M. Angiogenic factors. Science (Washington DC), 235: 442-447, 1987.
3. Adnane, J., Gaudray, P., Dionne, C. A., Crumley, G., Jaye, M., Schlessinger, J., Jeanteur, P., Birnbaum, D., and Theillet, C. BEK and FLG, two receptors to members of the FGF family, are amplified in subsets of human breast cancers. Oncogene, 6: 659-663, 1991.
4. Yoshida, T., Sakamoto, H., and Terada, M. Amplified genes in cancer in upper digestive tract. Semin. Cancer Biol., 4: 33-40, 1993.
5. Halaban, R. Growth factors and melanomas. Semin. Oncol., 23: 673-681, 1996.
6. Kornmann, M., Beger, H. G., and Korc, M. Role of fibroblast growth factors and their receptors in pancreatic cancer and chronic pancreatitis. Pancreas, 17: 169-175, 1998.
7. Cappellen, D., De Oliveira, C., Ricol, D., de Medina, S., Bourdin, J., Sastre-Garau, X., Chopin, D., Thiery, J. P., and Radvanyi, F. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat. Genet., 23: 18-20, 1999.
8. Risau, W. Mechanisms of angiogenesis. Nature (Lond.), 386: 671-674, 1997.
9. Terman, B. I., Dougher-Vermazen, M., Carrion, M. E., Dimitrov, D., Armellino, D. C., Gospodarowicz, D., and Bohlen, P. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem. Biophys. Res. Commun., 187: 1579-1586, 1999.
10. Ferrara, N. Molecular and biological properties of vascular endothelial growth factor. J. Mol. Med., 77: 527-543, 1999.
11. Yayon, A., Klagsbrun, M., Esko, J. D., Leder, P., and Ornitz, D. M. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell. 64: 841-848, 1991.
12. Rapraeger, A. C., Krufka, A., and Olwin, B. B. Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation. Science (Washington DC), 252: 1705-1707, 1991.
13. Gitay-Gorea, H., Soker, S., Vlodavsky, I., and Neufeld, G. The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules. J. Biol. Chem., 267: 6093-6098, 1992.
14. Aviezer, D., Hecht, D., Safran, M., Eisinger, M., David, G., and Yayon, A. Perlecan, basal lamina proteoglycan promotes bFGF-receptor binding, mitogenesis and angiogenesis. Cell, 79: 1005-1013, 1994.
15. Figge, F., Weiland, G., and Manganiello, L. Cancer detection and therapy. Affinity of neoplastic tissues for porphyrins and metalloporphyrins. Proc. Soc. Exp. Biol. Med., 68: 640, 1948.
16. Jori, G., Reddi, E., Cozzani, I., and Tomio, L. Controlled targeting of different subcellular sites by porphyrins in tumour-bearing mice. Br. J. Cancer, 53: 615-621, 1986.
17. Dougherty, T. J., Gomer, C. J., Henderson, B. W., Jori, G., Kessel, D., Korbelik, M., Moan, J., and Peng, Q. Photodynamic therapy. J. Natl. Cancer Inst., 90: 889-905, 1998.
18. Ornitz, D. M., Yayon, A., Flanagan, J. G., Svahn, C. M., Levi, E., and Leder, P. Heparin is required for cell-free binding of basic fibroblast growth factor to a soluble receptor and for mitogenesis in whole cells. Mol. Cell. Biol., 12: 240-247, 1992.
19. Tzahar, E., Waterman, H., Chen, X., Levkowitz, G., Karunagaran, D., Lavi, S., Ratzkin, B. J., and Yarden, Y. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol. Cell. Biol., 16: 5276-5287, 1996.
20. Gross, Z., Galili, N., and Saltsman, I. The first direct synthesis of corroles from pyrrole. Angew. Chem. Int. Ed. Eng., 38: 1427-1429, 1999.
21. Nicosia, R. F., and Ottinetti, A. Growth of microvessels in serum-free matrix culture of rat aorta. A quantitative assay of angiogenesis in vitro. Lab. Investig., 63: 115-122, 1990.
22. Nicosia, R. F., Nicosia, S. V., and Smith, M. Vascular endothelial growth factor, platelet-derived growth factor, and insulin-like growth factor-1 promote rat aortic angiogenesis in vitro. Am. J. Pathol., 145: 1023-1029, 1994.
23. O'Reilly, M. S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R. A., Moses, M., Lane, W. S., Cao, Y., Sage, E. H., and Folkman, J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell, 79: 315-328, 1994.
24. Miao, H. Q., Ornitz, D. M., Aingorn, E., Ben-Sasson, S. A., and Vlodavsky, I. Modulation of fibroblast growth factor-2 receptor binding, dimerization, signaling and angiogenic activity by a synthetic heparin-mimicking polyanionic compound. J. Clin. Investig., 99: 565-575, 1997.
25. Aviezer, D., and Yayon, A. Heparin-dependent binding and autophosphorylation of epidermal growth factor (EGF) receptor by heparin-binding EGF-like growth factor but not by EGF. Proc. Natl. Acad. Sci. USA, 91: 12173-12177, 1994.
26. Kan, M., Wang, F., Xu, J., Crabb, J. W., Hou. J., and McKeehan, W. L. An essential heparin-binding domain in the fibroblast growth factor receptor kinase. Science (Washington DC), 259: 1918-1921, 1993.
27. Li, L. Y., Safran, M., Aviezer, D., Bohlen, P., Seddon, A. P., and Yayon, A. Diminished heparin binding of a basic fibroblast growth factor mutant is associated with reduced receptor binding, mitogenesis, plasminogen activator induction, and in vitro angiogenesis. Biochemistry, 33: 10999-1007, 1994.
28. Schlessinger, J., Lax, I., and Lemmon, M. Regulation of growth factor activation by proteoglycans: what is the role of the low affinity receptors? Cell, 83: 357-360, 1995.
29. Plotnikov, A. N., Schlessinger, J., Hubbard, S. R., and Mohammadi, M. Structural basis for FGF receptor dimerization and activation. Cell, 98: 641-650, 1999.
30. Ornitz. D. M., Herr, A. B., Nilsson, M., Westman, J., Svahn, C. M., and Waksman, G. FGF binding and FGF receptor activation by synthetic heparan-derived di- and trisaccharides. Science (Washington DC), 268: 432-436, 1995.
31. Mohammadi, M., McMahon, G., Sun, L., Tang, C., Hirth, P., Yeh, B. K., Hubbard, S. R., and Schlessinger, J. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science (Washington DC), 276: 955-960, 1997.
32. Fong, T. A., Shawver, L. K., Sun, L., Tang, C., App, H., Powell, T. J., Kim, Y. H., Schreck, R., Wang, X., Risau, W., Ullrich, A., Hirth, K. P., and McMahon, G. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res., 59: 99-106, 1999.
33. Margaron, P., Madarnas, P., Quellet, R., and Van Lier, J. E. Biological activities of phthalocyanines. XVII. Histopathologic evidence for different mechanisms of EMT-6 tumor necrosis induced by photodynamic therapy with disulfonated aluminum phthalocyanine or photofrin. Anticancer Res., 16: 613-620, 1996.